Travere Therapeutics Highlights Advances in Rare Kidney and Metabolic Disease Therapies

Reuters11-17

Travere <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Highlights Advances in Rare Kidney and Metabolic Disease Therapies

Travere Therapeutics Inc. has released an update highlighting its strategic priorities and recent developments in rare kidney and metabolic diseases. The company detailed progress with FILSPARI (sparsentan), noting its position as the only fully approved kidney-targeted therapy for IgA nephropathy (IgAN) and its inclusion in the 2025 KDIGO guidelines for earlier, first-line use in patients at risk of disease progression. The U.S. FDA has reduced liver monitoring requirements for FILSPARI and removed the embryo-fetal toxicity REMS requirement. Travere is also preparing for a potential FDA approval and launch of FILSPARI for focal segmental glomerulosclerosis $(FSGS)$, with a Prescription Drug User Fee Act (PDUFA) target action date set for January 13, 2026. The company continues to advance its pegtibatinase development program and explore new opportunities for growth through external innovation. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on November 16, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584615760?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 12:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584615760","market":"us","top_or_hot":-1,"title":"Travere Therapeutics Highlights Advances in Rare Kidney and Metabolic Disease Therapies","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Highlights Advances in Rare Kidney and Metabolic Disease Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Travere Therapeutics Inc. has released an update highlighting its strategic priorities and recent developments in rare kidney and metabolic diseases. The company detailed progress with FILSPARI (sparsentan), noting its position as the only fully approved kidney-targeted therapy for IgA nephropathy (IgAN) and its inclusion in the 2025 KDIGO guidelines for earlier, first-line use in patients at risk of disease progression. The U.S. FDA has reduced liver monitoring requirements for FILSPARI and removed the embryo-fetal toxicity REMS requirement. Travere is also preparing for a potential FDA approval and launch of FILSPARI for focal segmental glomerulosclerosis <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a>, with a Prescription Drug User Fee Act (PDUFA) target action date set for January 13, 2026. The company continues to advance its pegtibatinase development program and explore new opportunities for growth through external innovation. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on November 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Travere Therapeutics Highlights Advances in Rare Kidney and Metabolic Disease Therapies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTravere Therapeutics Highlights Advances in Rare Kidney and Metabolic Disease Therapies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-17 12:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Travere <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Highlights Advances in Rare Kidney and Metabolic Disease Therapies\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Travere Therapeutics Inc. has released an update highlighting its strategic priorities and recent developments in rare kidney and metabolic diseases. The company detailed progress with FILSPARI (sparsentan), noting its position as the only fully approved kidney-targeted therapy for IgA nephropathy (IgAN) and its inclusion in the 2025 KDIGO guidelines for earlier, first-line use in patients at risk of disease progression. The U.S. FDA has reduced liver monitoring requirements for FILSPARI and removed the embryo-fetal toxicity REMS requirement. Travere is also preparing for a potential FDA approval and launch of FILSPARI for focal segmental glomerulosclerosis <a href=\"https://laohu8.com/S/FSGS\">$(FSGS)$</a>, with a Prescription Drug User Fee Act (PDUFA) target action date set for January 13, 2026. The company continues to advance its pegtibatinase development program and explore new opportunities for growth through external innovation. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on November 16, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL4R9v3R:1","article_id":"2584615760","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584615760","pubTimestamp":1763352667,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Travere Therapeutics Inc. has released an update highlighting its strategic priorities and recent developments in rare kidney and metabolic diseases. The company detailed progress with FILSPARI , noting its position as the only fully approved kidney-targeted therapy for IgA nephropathy  and its inclusion in the 2025 KDIGO guidelines for earlier, first-line use in patients at risk of disease progression. The U.S. FDA has reduced liver monitoring requirements for FILSPARI and removed the embryo-fetal toxicity REMS requirement. Travere is also preparing for a potential FDA approval and launch of FILSPARI for focal segmental glomerulosclerosis , with a Prescription Drug User Fee Act  target action date set for January 13, 2026. The company continues to advance its pegtibatinase development program and explore new opportunities for growth through external innovation. You can access the full presentation through the link below.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Travere Therapeutics强调罕见肾脏和代谢疾病疗法的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":0.9},"content_text":"Travere Therapeutics Highlights Advances in Rare Kidney and Metabolic Disease Therapies\n    \n\n        Travere Therapeutics Inc. has released an update highlighting its strategic priorities and recent developments in rare kidney and metabolic diseases. The company detailed progress with FILSPARI (sparsentan), noting its position as the only fully approved kidney-targeted therapy for IgA nephropathy (IgAN) and its inclusion in the 2025 KDIGO guidelines for earlier, first-line use in patients at risk of disease progression. The U.S. FDA has reduced liver monitoring requirements for FILSPARI and removed the embryo-fetal toxicity REMS requirement. Travere is also preparing for a potential FDA approval and launch of FILSPARI for focal segmental glomerulosclerosis $(FSGS)$, with a Prescription Drug User Fee Act (PDUFA) target action date set for January 13, 2026. The company continues to advance its pegtibatinase development program and explore new opportunities for growth through external innovation. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief on November 16, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584615760","isCrawlerRequest":true}